Advertisement
Advertisement
U.S. markets close in 1 hour 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

United Therapeutics Corporation (UTHR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
224.89+1.45 (+0.65%)
As of 02:45PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close223.44
Open223.60
Bid224.84 x 1000
Ask225.07 x 800
Day's Range221.93 - 225.69
52 Week Range158.38 - 245.48
Volume98,101
Avg. Volume487,453
Market Cap10.236B
Beta (5Y Monthly)0.53
PE Ratio (TTM)17.02
EPS (TTM)13.21
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est250.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
13% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for UTHR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • United Therapeutics Corporation
    Analyst Report: United Therapeutics CorporationUnited Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
Advertisement
Advertisement